(ABCL) – Company Press Releases
-
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
-
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
-
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
-
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
-
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
-
AbCellera Announces Resignation of Board Member
-
AbCellera to Present at Upcoming Investor Conferences in March
-
AbCellera Reports Full Year 2023 Business Results
-
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
-
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
-
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
-
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
-
AbCellera Reports Q3 2023 Business Results
-
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
-
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
-
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
-
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
-
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
-
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
-
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
-
AbCellera Reports Q2 2023 Business Results
-
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
-
AbCellera to Report Second Quarter 2023 Financial Results on August 3, 2023
-
DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer
-
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
-
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
-
AbCellera Reports Q1 2023 Business Results
-
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
-
AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
-
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
-
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
-
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
-
AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
-
AbCellera Reports Full Year 2022 Business Results
-
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
-
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
-
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
-
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
-
AbCellera and AbbVie Partner to Advance New Antibody Therapies
-
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
-
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
-
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
-
AbCellera Reports Q3 2022 Business Results
-
AbCellera to Present at Upcoming Investor Conferences in November
-
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
-
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
-
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
-
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
-
AbCellera Reports Q2 2022 Business Results
-
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
Back to ABCL Stock Lookup
